US Pharm. 2010;35:50. 

Hospira finalized its $400 million acquisition of the generic injectables business of Orchid Chemicals & Pharmaceuticals. The deal includes Orchid's beta-lactam antibiotic formulations operations, encompassing its penicillin, cephalosporin, and carbapenem facilities, and an R&D site. “We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key antibiotics area, expand out global footprint, and enhance our ability to provide lower cost, high-quality products to patients,” said Hospira COO Terry Kearney.